Kinaset Therapeutics doses first patient in Phase 2b PANAIRAMA trial
The dose-ranging study evaluates three doses of frevecitinib, an inhaled pan-JAK inhibitor, in patients with severe asthma.
See the latest news and media coverage for Kinaset. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing inhaled respiratory disease treatments
kinasettherapeutics.comLast updated
In short: Kinaset dosed the first patient in its Phase 2b severe-asthma trial and raised $103 million.
The dose-ranging study evaluates three doses of frevecitinib, an inhaled pan-JAK inhibitor, in patients with severe asthma.
David Lubner joins as independent director and audit committee chair, while Thomas King steps down as chair amid the frevecitinib Phase 2b asthma program.
Led by RA Capital Management and Forge Life Science Partners, proceeds advance the inhaled pan-JAK inhibitor frevecitinib through Phase 2 studies in severe asthma.
The company also gains an exclusive global license to KN-002, an inhaled pan-JAK inhibitor for severe asthma, with a Phase 1/1b trial planned for 1H 2021.
Kinaset Therapeutics, a clinical-stage biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases, announced it has closed a $103 million oversubscribed Series B...
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced two oral presentations and a late breaking poster...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Financing...
Kinaset Therapeutics, Inc. (“Kinaset” or the “Company”), a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a b...
Track Kinaset and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Kinaset and other trending companies.